StreetInsider.com News Articles

Form 8-K Maze Therapeutics, Inc. For: Oct 15

Fri, 16 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261016/27197964.html

Raymond James sees strong demand for APOL1-mediated FSGS therapies

Fri, 09 Oct 2026 05:52:23 -0400

Investing.com -- Raymond James maintained its Strong Buy rating on NASDAQ:MAZE and Market Perform rating on NASDAQ:VRTX after reviewing survey data from Spherix Global Insights on the focal segmental glomerulosclerosis market and APOL1-mediated kidney disease. The survey of 110 nephrologists was conducted in August 2026.

FSGS is a severe proteinuric kidney disease with high unmet need. Mutation in APOL1 contributes to approximately 75% of Black FSGS patients, and AMKD does not have an approved targeted therapeutic. MAZE and VRTX are both developing APOL1 inhibitors to treat this condition, with inaxaplin for VRTX and MZE829 for MAZE.

The survey data showed AMKD is

Raymond James sees strong demand for APOL1-mediated FSGS therapies

Fri, 09 Oct 2026 05:52:23 -0400

The survey data showed AMKD is

Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026

Tue, 06 Oct 2026 16:05:00 -0400

Oral presentation will highlight previously reported Phase 2 HORIZON data for MZE829 in patients with APOL1-mediated kidney disease

Two poster presentations will highlight preclinical research supporting the therapeutic potential of SLC6A19 inhibition in chronic kidney disease

SOUTH SAN FRANCISCO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that the company will present data supporting its lead programs, MZE829 and MZE782, during the American Society of Nephrology (ASN) Kidney Week, being held October

Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026

Tue, 06 Oct 2026 16:05:00 -0400

Oral presentation will highlight previously reported Phase 2 HORIZON data for MZE829 in patients with APOL1-mediated kidney disease

Two poster presentations will highlight preclinical research supporting the therapeutic potential of SLC6A19 inhibition in chronic kidney disease

Form 4 Maze Therapeutics, Inc. For: Oct 01 Filed by: Coloma Jason V

Fri, 02 Oct 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20261002/27142343.html

Form 4 Maze Therapeutics, Inc. For: Oct 01 Filed by: Bernstein Harold

Fri, 02 Oct 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20261002/27142263.html

Form 144 Maze Therapeutics, Inc. Filed by: Bernstein Harold

Thu, 01 Oct 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20261001/27136284.html

Form 4 Maze Therapeutics, Inc. For: Sep 29 Filed by: Dandekar Atul

Thu, 01 Oct 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20261001/27135944.html

Form 144 Maze Therapeutics, Inc. Filed by: Coloma Jason V

Thu, 01 Oct 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20261001/27135760.html

Citi initiates coverage of Maze Therapeutics with Buy rating

Wed, 23 Sep 2026 06:39:23 -0400

(Updated - September 23, 2026 5:02 AM EDT)

Citi analyst Eric Joseph initiated coverage of Maze Therapeutics (NASDAQ: MAZE) with an Buy rating and a 12-month price target of $50.00

Joseph cited the company's lead program MZE829, describing it as exhibiting "a best-in-class oral APOL1 inhibitor profile for the treatment of AMKD," and noted that pipeline candidate MZE782 is a potential treatment for PKU.

Maze Therapeutics to Participate in Three Upcoming Investor Conferences

Wed, 02 Sep 2026 07:00:00 -0400

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that company management will participate in three upcoming investor conferences:

Wells Fargo 21^st Annual Healthcare Conference; fireside chat on Wednesday, September 9, 2026, at 9:30 a.m. ET
Citi 2026 Biopharma Back to School Summit; fireside chat on Thursday, September 10, 2026, at 2:20 p.m. ET
H.C. Wainwright 28^th Annual Global Investment Conference; fireside chat on Tuesday, September 15, 2026, at 9:00 a.m. ET

Maze Therapeutics to Participate in Three Upcoming Investor Conferences

Wed, 02 Sep 2026 07:00:00 -0400

Wells Fargo 21^st Annual Healthcare Conference; fireside chat on Wednesday, September 9, 2026, at 9:30 a.m. ET
Citi 2026 Biopharma Back to School Summit; fireside chat on Thursday, September 10, 2026, at 2:20 p.m. ET
H.C. Wainwright 28^th Annual Global Investment Conference; fireside chat on Tuesday, September 15, 2026, at 9:00 a.m. ET

TD Cowen Assumes Maze Therapeutics (MAZE) at Buy

Sat, 22 Aug 2026 07:55:28 -0400

TD Cowen analyst Phil assumes coverage on Maze Therapeutics (NASDAQ: MAZE) with a Buy rating.

For an analyst ratings summary and ratings history on Maze Therapeutics click here. For more ratings news on Maze Therapeutics click here.

Shares of Maze Therapeutics closed at $29.43 yesterday.

Form 4 Maze Therapeutics, Inc. For: Aug 13 Filed by: Kornowski Sophie

Mon, 17 Aug 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260817/26938668.html

Form 4 Maze Therapeutics, Inc. For: Aug 13 Filed by: Kornowski Sophie

Mon, 17 Aug 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260817/26938668.html

Form 4 Maze Therapeutics, Inc. For: Aug 13 Filed by: Johnson Paula A

Mon, 17 Aug 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260817/26938655.html

Form 4 Maze Therapeutics, Inc. For: Aug 13 Filed by: Johnson Paula A

Mon, 17 Aug 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260817/26938655.html

Form 3 Maze Therapeutics, Inc. For: Aug 13 Filed by: Kornowski Sophie

Mon, 17 Aug 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260817/26938626.html

Form 3 Maze Therapeutics, Inc. For: Aug 13 Filed by: Kornowski Sophie

Mon, 17 Aug 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260817/26938626.html

Form 3 Maze Therapeutics, Inc. For: Aug 13 Filed by: Johnson Paula A

Mon, 17 Aug 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260817/26938567.html

Form 3 Maze Therapeutics, Inc. For: Aug 13 Filed by: Johnson Paula A

Mon, 17 Aug 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260817/26938567.html

Form 8-K Maze Therapeutics, Inc. For: Aug 13

Mon, 17 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260817/26938164.html

Form 8-K Maze Therapeutics, Inc. For: Aug 13

Mon, 17 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260817/26938164.html

Form 4 Maze Therapeutics, Inc. For: Aug 13 Filed by: Bernstein Harold

Fri, 14 Aug 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260814/26932285.html